AVDL Avadel Pharmaceuticals Plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AVDL

Price (delayed)

$17.99

Market cap

$1.63B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2

Enterprise value

$1.63B

Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime ...

Highlights
AVDL's quick ratio has surged by 84% year-on-year and by 8% since the previous quarter
The debt has dropped by 73% year-on-year and by 36% since the previous quarter
The company's equity fell by 20% QoQ
Avadel Pharmaceuticals's net income has decreased by 17% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.avadel.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of AVDL
Market
Shares outstanding
90.58M
Market cap
$1.63B
Enterprise value
$1.63B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
18.41
Price to sales (P/S)
51.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
58.42
Earnings
Revenue
$27.96M
EBIT
-$150.89M
EBITDA
-$149.13M
Free cash flow
-$128.51M
Per share
EPS
-$2
Free cash flow per share
-$1.6
Book value per share
$0.98
Revenue per share
$0.35
TBVPS
$1.84
Balance sheet
Total assets
$164.7M
Total liabilities
$76.96M
Debt
$35.38M
Equity
$87.74M
Working capital
$97.35M
Liquidity
Debt to equity
0.4
Current ratio
3.64
Quick ratio
3.18
Net debt/EBITDA
-0.03
Margins
EBITDA margin
-533.3%
Gross margin
97%
Net margin
-573.2%
Operating margin
-493%
Efficiency
Return on assets
-90.4%
Return on equity
-211.6%
Return on invested capital
-139.7%
Return on capital employed
-118%
Return on sales
-539.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVDL stock price

How has the Avadel Pharmaceuticals stock price performed over time
Intraday
3.99%
1 week
-0.55%
1 month
4.47%
1 year
70.52%
YTD
27.41%
QTD
6.51%

Financial performance

How have Avadel Pharmaceuticals's revenue and profit performed over time
Revenue
$27.96M
Gross profit
$27.12M
Operating income
-$137.85M
Net income
-$160.28M
Gross margin
97%
Net margin
-573.2%
AVDL's operating margin has soared by 69% QoQ
The net margin has surged by 69% since the previous quarter
The company's operating income fell by 40% YoY
Avadel Pharmaceuticals's net income has decreased by 17% YoY

Growth

What is Avadel Pharmaceuticals's growth rate over time

Valuation

What is Avadel Pharmaceuticals stock price valuation
P/E
N/A
P/B
18.41
P/S
51.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
58.42
Avadel Pharmaceuticals's EPS has increased by 13% YoY and by 7% QoQ
The company's equity fell by 20% QoQ

Efficiency

How efficient is Avadel Pharmaceuticals business performance
The ROIC has plunged by 148% YoY and by 2% from the previous quarter
The ROE has soared by 93% YoY and by 35% from the previous quarter
Avadel Pharmaceuticals's return on sales has surged by 69% QoQ
AVDL's return on assets is down by 8% year-on-year but it is up by 3.6% since the previous quarter

Dividends

What is AVDL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVDL.

Financial health

How did Avadel Pharmaceuticals financials performed over time
The total assets is 114% more than the total liabilities
Avadel Pharmaceuticals's current ratio has soared by 101% YoY and by 14% from the previous quarter
AVDL's quick ratio has surged by 84% year-on-year and by 8% since the previous quarter
The debt is 60% smaller than the equity
Avadel Pharmaceuticals's debt to equity has soared by 106% YoY but it has decreased by 20% from the previous quarter
The debt has dropped by 73% year-on-year and by 36% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.